Catalog Number

ADT1670

Product Name

Trastuzumab Research Biosimilar

Product Description

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive.

CAS Number

180288-69-1

Chemical Formula

C6470H10012N1726O2013S42

Clonity

Monoclonal

Target

ERBB2 (HER2 ,Tyrosine kinase-type cell surface receptor HER2,MLN19,Metastatic lymph node gene 19 protein,ERBB2,Proto-oncogene Neu,p185erbB2,CD_antigen=CD340,Proto-oncogene c-ErbB-2,MLN 19,NEU,Receptor tyrosine-protein kinase erbB-2,NGL) [Homo sapiens]

Alias

Trastuzumab Research Biosimilar

Host

CHO Cells

Isotype

man IgG1

Size

1mg,5mg

Molecular Weight

145.00 KDa

Mechanism of Action

Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers. The HER-2 receptor is a transmembrane tyrosine kinase receptor that consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular or cytoplasmic tyrosine kinase domain. It is activated by the formation of homodimers or heterodimers with other EGFR proteins, leading to dimerization and autophosphorylation and/or transphosphorylation of specific tyrosine residues in EGFR intracellular domains. Further downstream molecular signaling cascades are activated, such as the Ras/Raf/mitogen-activated protein kinase (MAPK), the phosphoinositide 3-kinase/Akt, and the phospholipase Cγ (PLCγ)/protein kinase C (PKC) pathways that promote cell growth and survival and cell cycle progression. Due to upregulation of HER-2 in tumour cells, hyperactivation of these signaling pathways and abnormal cell proliferation is observed. Trastuzumab binds to the extracellular ligand-binding domain and blocks the cleavage of the extracellular domain of HER-2 to induce its antibody-induced receptor downmodulation, and subsequently inhibits HER-2-mediated intracellular signaling cascades. Inhibition of MAPK and PI3K/Akt pathways lead to an increase in cell cycle arrest, and the suppression of cell growth and proliferation. Trastuzumab also mediates the activation of antibody-dependent cell-mediated cytotoxicity (ADCC) by attracting the immune cells, such as natural killer (NK) cells, to tumor sites that overexpress HER-2. While the drug alone has a minimal potential to induce complement-dependent cytotoxicity (CDC), one study demonstrated increased therapeutic effectiveness and a synergistic effect on uterine serous carcinoma cells in vitro when used in combination with pertuzumab, which also has minor effects on CDC alone. This study showed that only the combination of both cell-bound antibodies would be sufficient to bind and activate the complement component 1q (C1q) required to initiate the complement cascade reaction.

Metabolism

After it binds to HER2, trastuzumab is metabolized intracellularly into smaller peptides and amino acids.

Buffer

Supplied in PBS, PH7.5

Concentration

Batch dependent, please contact our customer service to get the COAs of current batch

Purity

>95% as determined by SDS-PAGE

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

This product is shipped in blue ice.